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Abstract. Substantiation of the ethiopathogenic choice of substitution therapy medications for the dry eye 
syndrome. Kryvoviaz O.V., Tomashevska Yu.O., Makarenko O.V., Kudria V.V. The purpose of the study is to 
substantiate the personalized selection of substitution therapy medications with the consideration of the pathogenesis of 
dry eye syndrome development in each patient. In order to achieve the set goal, we conducted a content-analysis of the 
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information from nomenclature on active ingredient as well as on the mechanisms of action of substitution therapy 
medications provided in the prescribing information and labeling of the medications. After that, we performed a 
pathogenetic ranging of substitution therapy medications depending on the way they influence a certain aspect of 
disorder of the tear film renewal process in dry eye syndrome. The information received in the course of the conducted 
research makes it possible for an ophthalmologist – basing on information on the disorder in the quantitative and 
qualitative correlation between the tear film layers received with the help of modern diagnostic tools to prescribe 
targeted dry eye syndrome treatment taking into account the necessary point of application of the substitution therapy 
medications, considering their composition and action mechanism of the active ingredients which they contain. 
 
Реферат. Обґрунтування етіопатогенетичного вибору засобів замісної терапії синдрому сухого ока. 
Кривов’яз О.В., Томашевська Ю.О., Макаренко О.В., Кудря В.В. Метою роботи стало обґрунтування 
індивідуалізованого вибору засобів замісної терапії з урахуванням патогенезу розвитку синдрому сухого ока в 
кожного окремого пацієнта. Для досягнення поставленої мети було здійснено контент-аналіз інформації з 
номенклатури активних інгредієнтів та механізмів дії засобів замісної терапії, наведеної в інструкціях для 
медичного застосування лікарського засобу, інструкціях з використання медичного виробу та інструкціях із 
застосування. Наступним етапом роботи було здійснене патогенетичне ранжування ЗЗТ залежно від їх 
впливу на  певну ланку порушення процесу оновлення слізної плівки при синдромі сухого ока. Отримана в резуль-
таті проведеного дослідження інформація дає можливість лікарю-офтальмологу, базуючись на результатах 
порушення кількісного та якісного співвідношення шарів слізної плівки, отриманих за допомогою новітніх 
засобів діагностики, прицільно здійснювати лікування синдрому сухого ока з урахуванням необхідної точки 
прикладання дії засобів замісної терапії, зважаючи на вміст та механізм дії активних інгредієнтів у них. 
 
The international medical and pharmaceutical 
community notice the increased influence of the di-
seases of civilization on people’s health and quality 
of life. Particularly, the dry eye syndrome (DES) has 
become especially important over the last decade [4, 
5, 8]. This is proved by the data on the spread of the 
stated pathology. Thus, it is noted that 10-30% of 
laboring population suffer from DES. In addition, 
about 75% of the patients who visit an ophthalmo-
logist, claim to have at least some symptoms of this 
syndrome [7]. Moreover, the establishment and 
active work of the working groups with the partici-
pation of health care specialists from all continents 
also confirm the increasing level of specialists’ 
interest [5, 6, 7, 8, 9, 10]. 
According to the definition, adopted at the 2017 
International Dry Eye Workshop II in 2017, DES is 
characterized by a loss of homeostasis of the tear 
film (TF), and accompanied by ocular symptoms, in 
which tear film instability plays an etiological role 
[5]. Ukraine is no exception. 
Despite the spread of DES in ophthalmological 
patients and a wide spectrum of DES substitution 
therapy medications (STMs) present on the national 
market [1, 2, 3], the treatment of this category of 
patients is predominantly empirical, without the 
consideration of the pathogenetic mechanism of 
disorder of the tear film renewal process. However, 
modern diagnostic tools allow to determine the 
pathogenetic mechanisms of DES development, 
particularly, to determine the layer (layers) of the 
tear film, the disorder of which caused the deve-
lopment of DES in this concrete patient. Based on 
this data, it is possible to make personalized selec-
tion of substitution therapy medications [5, 6, 9, 10]. 
Tear film is composed of three layers: mucin 
layer, aqueous layer and lipid layer, each of which 
performs certain functions [5, 10]. A thin mucin 
layer contacts with corneal epithelium and has a 
metabolic (ensures the delivery of nutrients to 
corneal epithelium as well as the removal of meta-
bolites; facilitates corneal epithelium regeneration; 
ensures hydration of epithelial cells) as well as light-
refracting functions (evens out the surface of the 
outer membrane of corneal epithelium; keeps the 
tear film on the outer membrane of the corneal 
epithelium and conjunctiva) [6, 10]. In addition to 
the functions described above the aqueous layer, 
which is the largest in volume, performs a protective 
function. The metabolic function of the aqueous 
layer lies in transport of oxygen, nutrients and a 
removal of metabolites, dead epithelial cells; in 
facilitation in corneal epithelium regeneration in 
ensuring the hydration of epithelial cells. The 
aqueous layer is the basis of the natural “contact 
lens” presented in the form of pre-corneal tear film, 
which ensures its light-refracting function. The pro-
tective function lies in the mechanical removal 
(washing off) of foreign bodies from the surface of 
corneal epithelial; in the anti-bacterial and anti-virus 
activity; in restoration of pH-level of the tear liquid 
in case when weak acids and/or alkali penetrate the 
conjunctival cavity [9, 10]. The lipid layer is 
external and has a protective (prevents various 
aerosols from penetrating the corneal epithelium, 
including the airborne infections pathogens; 
provides thermal isolation of the corneal epithelium 
and conjunctiva; decreases the evaporation of the 
aqueous layer) and light-refractory (evens the outer 
surface of the tear film) functions [5, 9, 10]. 
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That is why the purpose of the study is to 
substantiate the personalized selection of substitution 
therapy medications with the consideration of the 
pathogenesis of DES development in each patient. 
MATERIALS AND METHODS OF RESEARCH  
In order to achieve the set goal, we conducted a 
content-analysis of the information on active ingredient 
from nomenclature as well as on the mechanisms of 
STMs action provided in the prescribing information 
and labeling of the medications. After that we 
performed a pathogenetic ranging of STMs depending 
on the way they influence a certain aspect of disorder 
of the tear film renewal process under DES. 
RESULTS AND DISCUSSION 
STMs’ action in DES is determined by the pre-
sence of hyaluronic acid in their composition in the 
form of sodium hyaluronate (either in a clear form or 
in combination with propylene glycol and guar), 
carbopol, methyl cellulose derivatives (hypromelose 
and carmellose), polyquad, povidone, polyvinyl alco-
hol, dexpanthenol with taurine, trehalose, vitamin 
complex with amino acids, ectoin, Omega-3 [1-4, 8]. 
Hyaluronic acid has a chemical structure, mole-
cular mass and rheological properties similar to a 
component of human tears, namely, mucin. Because 
of its properties, hyaluronic acid moistures the eye 
not affecting the vision. In addition, its ability to 
bind water allows to keep the ocular surface lub-
ricated. When applied locally, hyaluronic acid 
increases the stability of the pre-corneal tear film, 
positively influences the epithelial layer, facilitates 
the increase in the tear liquid volume and corneal 
wetness, decreases tear evaporation from the ocular 
surface as well [3, 8]. Carbopol is a high-molecular 
carboxyvinyl polymer that increases the viscosity of 
the tear liquid. A drop of the medication creates a 
protective and moisturizing film on the cornea [3, 8]. 
Hypromelose is soluble in water and is a derivative 
of a natural polymer of cellulose. It has high 
viscosity, thus slowing down liquid outflow and 
increasing the period of its contact with the cornea. 
It is a protector of corneal epithelium, it improves 
tear film stability, increases the contact period 
between the cornea and other active ingredients. 
Hypromelose facilitates the regeneration, stability 
and renewal of optic characteristics of the tear film, 
stimulates the regeneration of the ocular mucous 
membrane, normalizes cell metabolism, speeds up 
mitosis and increases the strength of collagen fibers, 
facilitates the improvement of energy processes, 
stimulates reparative processes in dystrophic 
disorders, normalizes the processes, distortion of 
which is accompanied by a considerable changes in 
the metabolism of ocular tissues, moisturizes and 
preserves the physiological properties of the ocular 
mucous membrane in condition of tear liquid 
insufficiency due to a quick onset of action and a 
long-lasting effect [3, 8]. Poluquad (polyquaternium-
1) is a high molecular polymeric compound (4,600 – 
11,000 Dalton) with a high charge density, which 
tends to increase liquid viscosity, thus influencing 
the influencing the biological accessibility of the 
medication and without having a pharmacological 
effect [3, 8]. Physico-chemical properties of povi-
done ensure its lubricating effect and the ability to 
absorb on the ocular surface, to lower the surface 
tension and increase the viscosity of water solutions. 
Spreading on the surface of cornea and conjunctiva, 
povidone acts as mucin substitute and prevents the 
development of eye irritation and, consequently, 
corneal epithelium dehydration [3, 8]. Polyvinyl 
alcohol has properties similar to the properties of 
mucin (substances that are produced by ocular 
conjunctiva) [3, 8]. Taurine is a sulphonic acid that 
the body synthesizes from the cysteine amino acid 
and plays a significant role in the tissue regeneration 
process. Taurine helps to improve the energy 
processes, stimulates the reparative process in case 
of dystrophic disorders, normalizes the processes, 
the disorder of which is accompanied by a con-
siderable change in ocular tissue metabolism [3, 8]. 
Trehalose is a disaccharide that has protective, 
lubricating, regeneration and anti-oxidant properties. 
It is a key factor of dehydration processes (slowing 
down metabolic processes in conditions of hydration 
deficiency), a natural osmoprotector and bio-pro-
tector [3, 8]. Ectoin is a natural cell protecting 
molecule, which has membrane- and lipid-stabi-
lizing properties, lowers the level of inflammation 
caused by irritation or conjunctiva dryness, which 
are the key symptoms of the dry eye syndrome. It 
lubricates the ocular surface and prevents its further 
dehydration. It stabilizes the lipid layer of the tear 
film and protects ocular cells from hyperosmolarity. 
It facilitates the regeneration of the dry and irritated 
conjunctiva [3, 8]. 
As dry eye syndrome often causes the lipid layer 
thinning, the substitution of lipids with lipid con-
taining tear substitutes and sprays is well grounded. 
That is why while choosing “artificial tear” for cases 
of increased evaporation of the tear film, one should 
first focus on medications which have a prosthetic 
effect on the lipid layer of the tear film, such as 
STMs containing omega-3 [3, 8]. Hydroxypropyl-
guar attracts water and keeps it on the ocular 
surface, facilitating the even distribution of the STM 
drop on the ocular surface, covering the affected 
segments like a protective plaster [3, 8]. Dexpan-
thenol is a B5 pro-vitamin, a derivative form and an 
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alcohol analogue of pantothenic acid. Dexpanthenol, 
which is a component of an STM, stimulates the 
regeneration of the mucous membrane of the ocular 
surface, normalizes cell metabolism, speeds up 
mitosis and increases the strength of collagen fibers. 
Thus it causes the regenerative, metabolic and a 
weak anti-inflammatory effect of the drops. After 
linking with coenzyme A, which is a co-factor of 
various reactions, catalyzed by ferments and accom-
panied by acetyl group migration, pantothenic acid 
acts as a vitamin [3, 8]. Propyleneglycol stabilizes 
the tear film, shortens its break-up time [3, 8]. 
In addition, STMs may contain a complex of 
vitamins, amino acids and phospholipids. Namely, 
vitamin A normalizes tissue metabolism, takes part 
in oxidation-reduction processes, synthesis of 
mucopolysaccharides, proteins and lipids, stimulates 
cell regeneration. Vitamin E is a natural anti-oxi-
dant; it protects cell membranes from oxidation 
related changes. Phospholipids distribute themselves 
on the ocular surface and form a film, which 
duplicates the lipid layer, acts as a barrier, decreases 
the evaporation of the aqueous layer of the tear film 
[3, 8]. Vitamins A and E have a calming and 
softening effect and in combination with pho-
spholipids provide functional support of the lipid 
component of the eyelids and stabilization of the 
lipid component of the tear film, which plays a 
crucial role in the protective function of the tear 
liquid and control of its evaporation [3, 8]. L-prolin 
is one of the most important components of the 
collagen protein – the basis of all human body 
tissues. It supports the normal state of the 
conjunctive tissues (sclera of the eye, vessels). L-
glycine is a central inhibitory neurotransmitter, 
improves metabolic processes. L-lysine has an anti-
inflammatory, anti-swelling and painkilling effect. 
L-leucine participates in protein synthesis, activates 
cell and humoral immune response, increases the 
function of phagocytes, activates the processes of 
biosynthesis of amino acids, their predecessors and 
metabolites, prevents metabolic disturbances, which 
occur under stress [3, 8]. 
Thus, generalizing the above mentioned infor-
mation, we have sorted the STMs by their influence 
of the tear film layers (table). 
 
Influence of the dry eye syndrome substitution therapy medications corresponding tear film layer 
Influence of the corresponding  
tear film layer 
Name of the STM 
aqueous mucin lipid 
SUPEROPTICTM KOMLIT eye drops 10 ml vial No.1 + + + 
LAKRISEK OFTA PLUS eye drops, 8 ml vial, sterile, No.1 + - + 
SYSTEIN BALANS ZASIB DLIA ZVOLOZHENNIA OCHEY 10 ml, No.1 + + + 
KRAPLI OCHNI AY-TI EKTOIN 0.5 ml ampulla, No.10 + + + 
KRAPLI OCHNI AY-TI EKTOIN PRO 0.5 ml ampulla, No.10 + + + 
KATIONORM KRAPLI OCHNI 10 ml emulsion, No.1 + + + 
VIDISIK ocular gel 0.2%, 10 g in a tube; 1 tube in a card box + + - 
OFTAGEL’®, ocular gel, 2.5 mg/g, 10 g in a vial; 1 vial in a card box + + - 
OFTAGEL’® UNO ocular gel, 2.5 mg/g + + - 
SIKAPOS ocular gel, 2 mg/g, 10 g in a tube, 1 or 3 tubes in a box + + - 
SHTUCHNI SLIOZY eye drops, 5 ml, or 10 ml, or 15 ml in a “Drop-Tainer®” dropper vial; 1 
dropper-vial in a box made of card 
+ + - 
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T a b l e  c o n t i n u a t i o n  
Influence of the corresponding  
tear film layer 
Name of the STM 
aqueous mucin lipid 
TEALOZ® DUO ROZCHYN OFTALMOLOHICHNYI 10 ml vial, sterile, No.1 + + - 
OPTINOL 0.21% or 0.4% eye drops 10 ml + + - 
OPTINOL® INTENSYV eye drops 10 ml No.1 + + - 
SUPEROPTIK AKVA eye drops 5 ml vial, No.1, 2 + + - 
AKVILA KRAPLI OCHNI eye drops 0.18 % polymer container 0.4 ml, sterile, No.10 + + - 
OKUTIARZ eye drops 10 ml vial, No.1 + + - 
OKUKHIL C KRAPLI OCHNI ZAKHYSNI solution 10 ml, No.1 + + - 
ARTELAK® SPLESK POZCHYN ZVOLOZHUYUCHYI DLIA OCHEY I KONTAKTNYKH 
LINZ 0.24 % solution, 10 ml vial, No.1 
+ + - 
KHILO-KOMOD eye drops 1 mg/ml, 10 ml in a multi-dose container, equipped with an air-tight 
pipe and closed with a cap, 1 container in a card box 
+ + - 
KHILO-KOMOD FORTE eye drops, 2 mg/ml, 10 ml in a multi-dose container, equipped with an 
air-tight pipe and closed with a cap, 1 container in a card box 
+ + - 
SYSTEIN ULTRA ZASIB DLIA ZVOLOZHENNIA OCHEY 10 ml vial. No.1, 0.7 ml container, 
No.30 
+ + - 
ZASIB DLIA ZVOLOZHENNIA OCHEY SYSTEIN® gel solution 10 ml No.1 + + - 
SYSTEIN AKVA ZASIB DLIA ZVOLOZHENNIA OCHEY 10 ml, No.1 + + - 
ZASIB D/ZVOLOZHEN. OCHEY SYSTEIN 10 ml vial, No.1 + + - 
OPTIVE® eye drops in 3 ml, 10 ml, 15 ml dropper vials No.1 + + - 
VIAL’® SLIOZA drops 10 ml polyethylene vial, No.1 + + - 
HIPROMELOZA-P, eye drops 0.5%, 10 ml dropper-container, No.1 + + - 
UNITIRS eye drops 10 ml vial, No.1 + + - 
ARTELAK® eye drops, solution, 3.2 ml/mg 10 ml in a vial with a dropper; 1 vial with a dropper in 
a box 
+ + - 
VIZILOTON ZASIB OFTALMOLOHICHNYI 10 ml, No,1 + + - 
OFTOLIK eye drops, 5 ml or 10 ml in a plastic dropper-vial; 1 dropper-vial in a card box + + - 
VET-KOMOD eye drops, 20 mg/ml 10 ml in a multi-dose plastic container, equipped with an air-
tight pipe; 1 container in a card box 
+ + - 
KHILO®-KEA eye drops 10 ml multi-dose container with a pipe and a cap, No.1 + - - 
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CONCLUSIONS 
The information received in the course of the 
conducted research makes it possible for an 
ophthalmologist to prescribe targeted DES treatment 
taking into account the necessary point of 
application of the  substitution  therapy medications 
considering   their  composition  and  mechanism of 
action of the active  ingredients  which  they  contain  
 
basing on the information on the distortion in the 
quantitative and qualitative correlation between the 
tear film layers receeved with the help of modern 
diagnostic tools. 
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